Brought to you by 
Roche signs antibody deal with Genmab
13 Jun 2013
Executive Summary
Using its UltiMAb antibody platform, Genmab will create new human antibodies for disease targets supplied by Roche. Genmab could receive milestones and sales royalties, and may get to develop some of the compounds itself.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche signs antibody deal with Genmab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice